NRG1
Merus Nabs FDA Accelerated Approval for Bizengri in NRG1 Fusion-Positive NSCLC, Pancreatic Cancer
The approval is based on overall response rates from the Phase II eNRGy study, which enrolled advanced, previously treated NRG1 fusion-positive patients.
Merus, Elevation Oncology Drugs Show Initial Activity in Lung, Pancreatic Cancers With NRG1 Fusions
Premium
The companies have pan-cancer ambitions for these drugs, and the data presented at ASCO are starting to show activity in specific NRG1 fusion-positive tumor types.